Abstract:Natural killer (NK) cell therapies are a tool to antagonize a dysfunctional immune system. NK cells recognize malignant cells, traffic to a tumor location, and infiltrate the solid tumor. The immune checkpoint molecule human leukocyte antigen (HLA)-G is upregulated on malignant cells but not on healthy surrounding cells, the requirement of understanding the basis of receptor mediated events at the HLA-G/NK cell interface becomes obvious. The NK cell receptors ILT2 and KIR2DL4 have been described to bind to HLA-G; however, their differential function and expression levels on NK cell subsets suggest the existence of an unreported receptor. Here, we performed a ligand-based receptor capture on living cells utilizing sHLA-G*01:01 molecules coupled to TriCEPS and bound to NK cells followed by mass spectrometric analyses. We could define NKG2A/CD94 as a cognate receptor of HLA-G. To verify the results, we used the reciprocal method by expressing recombinant soluble heterodimeric NKG2A/CD94 molecules and used them to target HLA-G*01:01 expressing cells. NKG2A/CD94 could be confirmed as an immune receptor of HLA-G*01:01. Despite HLA-G is marginal polymorphic, we could previously demonstrate that the most common allelic subtypes HLA-G*01:01/01:03 and 01:04 differ in peptide repertoire, their engagement to NK cells, their catalyzation of dNK cell proliferation and their impact on NK cell development. Continuing these studies with regard to NKG2A/CD94 engagement we engineered recombinant single antigen presenting K562 cells and targeted the surface expressed HLA-G*01:01, 01:03 or 01:04 molecules with NKG2A/CD94. Specificity and sensitivity of HLA-G*01:04/NKG2A/CD94 engagement could be significantly verified. The binding affinity decreases when using K562-G*01:03 or K562-G*01:01 cells as targets. These results demonstrate that the ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies.

CD94/NKG2A--A Kind of Inhibitory Receptor Belonging to C-type Lectin Superfamily

The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells

Role for NKG2-A and NKG2-C surface receptors in chronic CD4+ T-cell responses

Slowly getting a clue on CD95 ligand biology.

Biochemical and serologic evidence for the existence of functionally distinct forms of the CD94 NK cell receptor.

CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence

Expression of CD94 and NKG2 molecules on human CD4(+) T cells in response to CD3-mediated stimulation

Cutting edge: CD94/NKG2 is expressed on Th1 but not Th2 cells and costimulates Th1 effector functions

Regulation of Activated Cd4(+) T Cells by Nk Cells Via the Qa-1-Nkg2a Inhibitory Pathway

[Study on Expression of Natural Killer (NK) Cell C-type Lectin-Like Receptors in Nasal NK/T-cell Lymphomas].

NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain

NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division

HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells

Natural killer cell cytotoxicity and its regulation by inhibitory receptors

Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes

Klrl1, A Novel Killer Cell Lectinlike Receptor, Inhibits Natural Killer Cell Cytotoxicity

NKG2D Negatively Regulates CD4 T Cells in Allo-Response in Mice

The Biological Characteristic and Function of Dectin-2,a New C-type Lectin Receptor

Structure of the human NK cell NKR-P1:LLT1 receptor:ligand complex reveals clustering in the immune synapse

Expansion and Function of Cd8(+) T Cells, Expressing Ly49 Inhibitory Receptors Specific for Mhc Class I Molecules

Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor.